A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo
← catalyst calendarSponsored by SAb Biotherapeutics, Inc. (industry) · SABS — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
28actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-22 | actual | When the study began enrolling |
| Primary completion | 2025-02-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- PHA1A
Interventions
- Drug: Single Ascending Dose of SAB-176 — also filed as SAB-176
- Drug: Single Ascending Dose of Placebo — also filed as Placebo
Primary outcomes
what the primary-completion date above is the date OFOccurrence of solicited local and systemic adverse events (AEs) through Day 29.
measured Dosing through Day 29
Occurrence of IP-related unsolicited AEs through Day 61.
measured Dosing through Day 61
Occurrence of serious adverse events (SAEs) through Day 61.
measured Dosing through Day 61
Permalink · SABS's whole pipeline · Catalyst calendar · Every registered study · What changed